why choose us

First received: April 17, 2023

Clinical Trial: Promoting Repigmentation After Epidermal Cell Suspension Grafting and preVENTing the Loss of Melanocytes Using Topical Ruxolitinib for Vitiligo in Resistant Areas

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Vitiligo

Study Type: INTERVENTIONAL


Official Title: Promoting Repigmentation After Epidermal Cell Suspension Grafting and preVENTing the Loss of Melanocytes Using Topical Ruxolitinib for Vitiligo in Resistant Areas. Prospective Monocentric Intervention

Brief Summary: Medical approaches remain the gold standard treatment for non-segmental forms of vitiligo.Topical ruxolitinib cream has demonstrated its efficacy and good tolerance for treating vitiligo.While about 30% of patients will achieve at least 90% of repigmentation on the face after 1 year of treatment, some locations on the body, such as hands, feet, bony prominences remain highly challenging, and most patients won't get satisfactory repigmentation on those areas despite months of application of topical treatments,…

Read more